If Viking Therapeutics Is Acquired, Here’s Who Wins

By Trey Thoelcke Published May 26, 8:50AM EDT

Quick Read

Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target.
A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Viking Therapeutics wasn't one of them. Get them here FREE.

If Viking Therapeutics Is Acquired, Here’s Who Wins — © Pattanaphong Khuankaew / Getty Images

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not yet owned by Big Pharma. This scenario analysis examines who would actually benefit if a deal happens.

Why Viking Is the Most-Watched M&A Target

Viking is a clinical-stage biotech with no revenue and a market cap near $3.59 billion. Shares closed at $30.89 on May 22, 2026, down 12.2% year to date. Analyst sentiment, however, is striking, with almost all analysts rating it Buy or Strong Buy, and a mean target price all the way up at $92.33.

The lead asset is doing the talking. Oral VK2735 delivered up to 12.2% weight loss at 13 weeks, with 80% of participants achieving at least 10% weight loss. Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Cash burn is accelerating: Q4 2025 net loss hit $157.66 million against roughly $706 million in cash, sharpening the strategic clock.

Existing Shareholders Benefit

For current holders, the standalone case is the $92.33 analyst target, which assumes successful Phase 3 readouts. A deal would compress that timeline. Biotech buyouts of clinical-stage assets have historically closed well above prevailing prices, and recent obesity deals (notably Pfizer’s roughly $9.8 billion Metsera acquisition) set a reference point. Speculative buyout investing remains one of the highest-risk strategies in biotech: trial setbacks, regulatory delays, and deal breaks can all hit hard.

The Potential Buyer Benefits

Eli Lilly (NYSE: LLY) already dominates the category. Q1 2026 revenue of roughly $19.8 billion grew 55.5%, with Mounjaro and Zepbound leading. A second platform still adds optionality, though antitrust optics complicate the fit at its $949.7 billion market cap.

Pfizer (NYSE: PFE) has been the most active acquirer in obesity. CEO Albert Bourla said, “2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts.” A Phase 3-ready dual agonist would integrate directly into the Metsera pipeline buildout.

Novo Nordisk (NYSE: NVO) is defending share. Shares are down 33.2% over the past year, and 2026 guidance calls for adjusted sales growth of −4% to −12%. A defensive bid is plausible.

Merck and Amgen round out the longer-shot list. Merck is underweight obesity and already acquiring Terns Pharmaceuticals, while Amgen has MariTide advancing internally, which may reduce urgency rather than create it.

Competitors and the Industry Benefit

The clearest secondary winner is Structure Therapeutics (NASDAQ: GPCR), whose oral aleniglipron delivered 16.3% placebo-adjusted weight loss at 44 weeks. With a $2.8 billion market cap and a $106.47 average analyst target, Structure would inherit the scarcity premium if Viking is removed from the board. The Terns deal already shows Big Pharma’s willingness to consolidate metabolic assets.

For the broader industry, a Viking transaction would validate the tuck-in playbook, likely re-rate the obesity small-cap basket, and serve as an FTC test case for GLP-1 consolidation. It would also mark Polymarket as a usable M&A signal in biotech research.

The Bottom Line

Even with 61.5% odds priced against a deal, Viking remains at the center of the obesity M&A conversation. If a transaction occurs, shareholders, the acquirer, and the broader obesity basket all stand to gain. Worth watching: Phase 3 enrollment updates, oral VK2735 progress, and any Big Pharma business development signaling through the rest of 2026.

Follow 24/7 Wall St. on Google

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.